Insights
Search Results
Alerts
4.06.26
FTC Announcement of Healthcare Task Force Coincides with Joint DOJ/FTC Appearance at ONC Annual Meeting
Two recent developments suggest that enforcers are poised to grapple with antitrust concerns in health tech, signaling an escalation of scrutiny into Information Blocking1 tactics that have persisted despite U.S. Department of Health and Human Services (HHS) rules and regulations designed to curtail such practices. Stakeholders and industry participants should be prepared for potential outreach.
Alerts
2.18.26
Federal Court Vacates FTC’s 2024 HSR Form Rule; Order Stayed Seven Days Pending Appeal
On February 12, 2026, Judge Jeremy D. Kernodle of the U.S. District Court for the Eastern District of Texas granted summary judgment to plaintiffs U.S. Chamber of Commerce and other business groups, and vacated the 2024 Federal Trade Commission (FTC) rulemaking that significantly revised the Hart-Scott-Rodino (HSR) reporting requirements. The court concluded that the FTC exceeded its statutory rulemaking authority when it implemented the HSR reporting change, and such a change was arbitrary and capricious under the Administrative Procedure Act (APA). The court stayed its order for seven days to allow the FTC to seek an emergency appeal to the U.S. Court of Appeals for the Fifth Circuit. If the Fifth Circuit does not grant emergency relief before February 19, 2026, the current HSR rules will be vacated, and HSR reportable transactions will be filed under the HSR rules that were in effect prior to February 10, 2025, when the new HSR reporting rules went into effect.
Alerts
2.10.26
“Landmark” Settlement in PBM Case Poised to Broadly Reshape Prescription Drug Market
On February 4, 2026, the Federal Trade Commission (FTC) announced a settlement and consent order in a long-running administrative action against pharmacy benefit managers (PBMs) Express Scripts, OptumRx, and Caremark Rx. The FTC alleged that these three PBMs, which have a collective U.S. market share of approximately 80 percent, deployed anticompetitive and unfair rebating practices that artificially inflated the list price of insulin drugs by systematically preferring higher-priced drugs at the exclusion of lower cost products. The settlement resolves the claims as to Express Scripts and its family of companies.
Alerts
1.16.26
FTC Announces 2026 HSR Thresholds
On January 14, 2026, the Federal Trade Commission (FTC) released the revised Hart-Scott-Rodino (HSR) Act jurisdictional thresholds for 2026. The FTC is required by law to revise the HSR Act monetary jurisdictional thresholds each year based on changes in the gross national product. The revised thresholds will become effective 30 days after notice is published in the Federal Register and will apply to transactions closing on or after the effective date. The 2025 thresholds will remain applicable for transactions that close before the effective date.
Alerts
1.09.26
2026 Year in Preview: Regulatory Consumer Protection Trends for Companies to Watch Out For
As we ring in the new year, we want to make you aware of key issues affecting consumers that we expect lawmakers and regulators to focus on over the next 12 months. Below are the top transatlantic consumer protection issues to watch out for in 2026:
Alerts
11.07.25
What’s Happening at the FTC During the Government Shutdown?
The federal government has been shut down for over a month. We previously reported on implications for the Federal Trade Commission’s (FTC) antitrust work here. What does the shutdown mean for the FTC’s consumer protection, privacy, safety, and AI work?
Alerts
10.08.25
FTC and DOJ Officials Provide New Insights on the Administration’s Antitrust Agenda
Policies and priorities for U.S. competition agencies are coming into sharper focus as leadership settles in under the new administration. Last month’s Fordham Competition Law Institute’s 52nd Annual Conference on International Law and Policy plus Antitrust Economics Workshop offered a chance for leaders at the U.S. Department of Justice (DOJ) Antitrust Division and the Federal Trade Commission (FTC) to set out their vision.
Alerts
9.12.25
The Trump FTC Takes New Action Against Non-Competes, While Abandoning Defense of the Biden-Era Non-Compete Clause Rule
Demonstrating its focus on challenging non-competes through case-by-case enforcement, the Federal Trade Commission (FTC) recently undertook a series of actions. It announced a consent decree requiring Gateway Memorial Pet Services (Gateway), the largest pet cremation business in the United States, to immediately cease enforcement of non-compete agreements that the FTC alleged “limit [employee] job mobility and the ability to negotiate better wages and benefits."1 Along with that action, the FTC also issued a broad Request for Information (“RFI”), inviting members of the public to provide information on non-compete agreements that they themselves may be subject to or have knowledge regarding so the FTC can investigate further and bring enforcement action as appropriate. The following day, the FTC announced it would abandon its appeals in Ryan, LLC v. FTC, No. 24-10951 (5th Cir.), and Properties of the Villages v. FTC, No. 24-13102 (11th Cir.), and to accede to the order in Ryan setting aside the Biden-era Non-Compete Clause Rule.
Press Releases
8.13.25
Thirteen Wilson Sonsini Attorneys Appointed to American Bar Association Antitrust Leadership Roles
Palo Alto, CA (August 13, 2025) — Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, is proud to announce that 12 of its attorneys have been appointed to leadership roles within the American Bar Association (ABA) for the 2025–2026 term. Of these, 11 will serve in the ABA’s Antitrust Law Section—the world’s foremost community of competition and consumer protection professionals, with more than 7,000 members globally. Additionally, one attorney has been named to the ABA’s Business Law Section, one of the organization’s largest sections focused on business, corporate, and commercial law matters.
Alerts
6.16.25
DOJ Carries Through on Revitalization of Merger Remedies
Days after the Federal Trade Commission (FTC) reached its first divestiture settlement of the new Trump administration, the U.S. Department of Justice Antitrust Division (DOJ or the Division) followed through on Assistant Attorney General Abigail Slater’s (AAG Slater) prior comments by announcing its first remedy of the new Trump Administration. During her confirmation hearing, AAG Slater noted that under her leadership the Division would “take a different approach than the prior Antitrust Division on settlements in merger cases where effective and robust structural remedies can be implemented without excessively burdening the Antitrust Division’s resources.”1
Alerts
6.02.25
And Just Like That: Remedies Are Back at the FTC
The Federal Trade Commission (FTC or Commission) recently announced that it will require Synopsys, Inc. (Synopsys) and Ansys, Inc. (Ansys) (together, “the parties”) to divest certain assets to resolve antitrust concerns surrounding the parties $35 billion merger.1 The Proposed Order is the first instance of the Commission clearing a merger subject to a remedy under the new Trump Administration. The Commission’s willingness to resolve competitive concerns about a merger through divestiture confirms the return to the status quo—before the Biden Administration and FTC Chair Lina Khan—where parties to a merger may work with the FTC to find a structural solution that resolves the anticompetitive concerns presented by a merger while preserving its procompetitive benefits.
Alerts
4.28.25
FTC Files Consumer Protection Complaint Against Uber for Deceptive Billing and Cancellation Practices
On April 21, 2025, the Federal Trade Commission (FTC) announced that it had filed a complaint against Uber Technologies, Inc. and Uber USA LLC (collectively, Uber), a rideshare and delivery company. Among other things, the FTC alleges in its complaint that Uber violated Section 5 of the FTC Act and the Restore Online Shoppers’ Confidence Act (ROSCA) by charging consumers for its Uber One subscription service without their consent and making it difficult for users to cancel the service despite its “cancel anytime” promises.